622 related articles for article (PubMed ID: 30111356)
1. Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup.
Woollacott IOC; Nicholas JM; Heslegrave A; Heller C; Foiani MS; Dick KM; Russell LL; Paterson RW; Keshavan A; Fox NC; Warren JD; Schott JM; Zetterberg H; Rohrer JD
Alzheimers Res Ther; 2018 Aug; 10(1):79. PubMed ID: 30111356
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal Fluid YKL-40 and Chitotriosidase Levels in Frontotemporal Dementia Vary by Clinical, Genetic and Pathological Subtype.
Woollacott IOC; Nicholas JM; Heller C; Foiani MS; Moore KM; Russell LL; Paterson RW; Keshavan A; Schott JM; Warren JD; Heslegrave A; Zetterberg H; Rohrer JD
Dement Geriatr Cogn Disord; 2020; 49(1):56-76. PubMed ID: 32344399
[TBL] [Abstract][Full Text] [Related]
3. CSF sTREM2 in delirium-relation to Alzheimer's disease CSF biomarkers Aβ42, t-tau and p-tau.
Henjum K; Quist-Paulsen E; Zetterberg H; Blennow K; Nilsson LNG; Watne LO
J Neuroinflammation; 2018 Nov; 15(1):304. PubMed ID: 30390679
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid soluble TREM2 in aging and Alzheimer's disease.
Henjum K; Almdahl IS; Årskog V; Minthon L; Hansson O; Fladby T; Nilsson LN
Alzheimers Res Ther; 2016 Apr; 8(1):17. PubMed ID: 27121148
[TBL] [Abstract][Full Text] [Related]
5. CSF sTREM2 is elevated in a subset in GRN-related frontotemporal dementia.
van der Ende EL; Morenas-Rodriguez E; McMillan C; Grossman M; Irwin D; Sanchez-Valle R; Graff C; Vandenberghe R; Pijnenburg YAL; Laforce R; Ber IL; Lleo A; Haass C; Suarez-Calvet M; van Swieten JC; Seelaar H
Neurobiol Aging; 2021 Jul; 103():158.e1-158.e5. PubMed ID: 33896652
[TBL] [Abstract][Full Text] [Related]
6. Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-β pathology.
Suárez-Calvet M; Morenas-Rodríguez E; Kleinberger G; Schlepckow K; Araque Caballero MÁ; Franzmeier N; Capell A; Fellerer K; Nuscher B; Eren E; Levin J; Deming Y; Piccio L; Karch CM; Cruchaga C; Shaw LM; Trojanowski JQ; Weiner M; Ewers M; Haass C;
Mol Neurodegener; 2019 Jan; 14(1):1. PubMed ID: 30630532
[TBL] [Abstract][Full Text] [Related]
7. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease.
Heslegrave A; Heywood W; Paterson R; Magdalinou N; Svensson J; Johansson P; Öhrfelt A; Blennow K; Hardy J; Schott J; Mills K; Zetterberg H
Mol Neurodegener; 2016 Jan; 11():3. PubMed ID: 26754172
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal Fluid sTREM2 in Alzheimer's Disease Is Associated with Both Amyloid and Tau Pathologies but not with Cognitive Status.
Li TR; Lyu DY; Liu FQ;
J Alzheimers Dis; 2022; 90(3):1123-1138. PubMed ID: 36213998
[TBL] [Abstract][Full Text] [Related]
9. CSF pro-orexin and amyloid-β38 expression in Alzheimer's disease and frontotemporal dementia.
Heywood WE; Hallqvist J; Heslegrave AJ; Zetterberg H; Fenoglio C; Scarpini E; Rohrer JD; Galimberti D; Mills K
Neurobiol Aging; 2018 Dec; 72():171-176. PubMed ID: 30292090
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia.
Landqvist Waldö M; Frizell Santillo A; Passant U; Zetterberg H; Rosengren L; Nilsson C; Englund E
BMC Neurol; 2013 May; 13():54. PubMed ID: 23718879
[TBL] [Abstract][Full Text] [Related]
11. Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer's disease.
Morenas-Rodríguez E; Alcolea D; Suárez-Calvet M; Muñoz-Llahuna L; Vilaplana E; Sala I; Subirana A; Querol-Vilaseca M; Carmona-Iragui M; Illán-Gala I; Ribosa-Nogué R; Blesa R; Haass C; Fortea J; Lleó A
Sci Rep; 2019 May; 9(1):7803. PubMed ID: 31127154
[TBL] [Abstract][Full Text] [Related]
12. Glial activation and inflammation along the Alzheimer's disease continuum.
Nordengen K; Kirsebom BE; Henjum K; Selnes P; Gísladóttir B; Wettergreen M; Torsetnes SB; Grøntvedt GR; Waterloo KK; Aarsland D; Nilsson LNG; Fladby T
J Neuroinflammation; 2019 Feb; 16(1):46. PubMed ID: 30791945
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid sTREM2 in Alzheimer's disease: comparisons between clinical presentation and AT classification.
Knapskog AB; Henjum K; Idland AV; Eldholm RS; Persson K; Saltvedt I; Watne LO; Engedal K; Nilsson LNG
Sci Rep; 2020 Sep; 10(1):15886. PubMed ID: 32985583
[TBL] [Abstract][Full Text] [Related]
14. The relationship of soluble TREM2 to other biomarkers of sporadic Alzheimer's disease.
Park SH; Lee EH; Kim HJ; Jo S; Lee S; Seo SW; Park HH; Koh SH; Lee JH
Sci Rep; 2021 Jun; 11(1):13050. PubMed ID: 34158530
[TBL] [Abstract][Full Text] [Related]
15. Neuroinflammatory CSF biomarkers MIF, sTREM1, and sTREM2 show dynamic expression profiles in Alzheimer's disease.
Hok-A-Hin YS; Del Campo M; Boiten WA; Stoops E; Vanhooren M; Lemstra AW; van der Flier WM; Teunissen CE
J Neuroinflammation; 2023 May; 20(1):107. PubMed ID: 37147668
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-3 is associated with sTREM2 and mediates the correlation between amyloid-β and tau pathology in Alzheimer's disease.
Wang ZB; Ma YH; Sun Y; Tan L; Wang HF; Yu JT;
J Neuroinflammation; 2022 Dec; 19(1):316. PubMed ID: 36578067
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal Fluid Biomarkers in Patients with Frontotemporal Dementia Spectrum: A Single-Center Study.
Abu-Rumeileh S; Mometto N; Bartoletti-Stella A; Polischi B; Oppi F; Poda R; Stanzani-Maserati M; Cortelli P; Liguori R; Capellari S; Parchi P
J Alzheimers Dis; 2018; 66(2):551-563. PubMed ID: 30320576
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias.
de Souza LC; Lamari F; Belliard S; Jardel C; Houillier C; De Paz R; Dubois B; Sarazin M
J Neurol Neurosurg Psychiatry; 2011 Mar; 82(3):240-6. PubMed ID: 20802215
[TBL] [Abstract][Full Text] [Related]
19. Soluble TREM2 changes during the clinical course of Alzheimer's disease: A meta-analysis.
Liu D; Cao B; Zhao Y; Huang H; McIntyre RS; Rosenblat JD; Zhou H
Neurosci Lett; 2018 Nov; 686():10-16. PubMed ID: 30171911
[TBL] [Abstract][Full Text] [Related]
20. Soluble TREM2 is elevated in Parkinson's disease subgroups with increased CSF tau.
Wilson EN; Swarovski MS; Linortner P; Shahid M; Zuckerman AJ; Wang Q; Channappa D; Minhas PS; Mhatre SD; Plowey ED; Quinn JF; Zabetian CP; Tian L; Longo FM; Cholerton B; Montine TJ; Poston KL; Andreasson KI
Brain; 2020 Mar; 143(3):932-943. PubMed ID: 32065223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
